Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse

World Journal of Biological Psychiatry

Volumn 10, Issue 4 PART 2, 2009, Pages 599-602

  Marchesi, Carlo ^a   Tonna, Matteo ^a   Maggini, Carlo ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Ecstasy; Major depression; Obsessive compulsive disorder; Psychosis; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CLOMIPRAMINE; OLANZAPINE; RISPERIDONE; SERTRALINE; BENZODIAZEPINE DERIVATIVE; DOPAMINE; NEUROLEPTIC AGENT; PSYCHEDELIC AGENT; SEROTONIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; HUMAN; LABORATORY TEST; MALE; NUCLEAR MAGNETIC RESONANCE; OBSESSIVE COMPULSIVE DISORDER; PHYSICAL EXAMINATION; SUBSTANCE ABUSE; BORDERLINE STATE; BRAIN; CHEMICALLY INDUCED DISORDER; COMORBIDITY; DRUG ABUSE; DRUG EFFECT; FEMALE; GENETIC PREDISPOSITION; GENETICS; MAJOR DEPRESSION; METABOLISM; PSYCHOLOGICAL ASPECT; PSYCHOSIS; RISK FACTOR; WITHDRAWAL SYNDROME;

ADOLESCENT; AMPHETAMINE-RELATED DISORDERS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BORDERLINE PERSONALITY DISORDER; BRAIN; CLOMIPRAMINE; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DOPAMINE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HALLUCINOGENS; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOSES, SUBSTANCE-INDUCED; RISK FACTORS; RISPERIDONE; SEROTONIN; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 77449151579     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970701459828     Document Type: Article

References (25)

1. Aouizerate B, Guehl D, Cuny E, et al. 2004. Pathophysiology of obsessive-compulsive disorder. A necessary link between phenomenology, neuropsychology, imagery and physology. Prog Neurobiol 72:195-221.
2. Bottas A, Cooke RG, Richter MA. 2005. Comorbidity and pathophysiology of obsessive-compulsive disorder in schizophrenia: is there evidence for a schizo-obsessive subtype of schizophrenia? J Psychiatr Neurosci 30:187-193.
3. Chamberlain SR, Blackwell AD, Fineberg NA, Robbins TW, Sahakian BJ. 2005. The neuopsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioral inhibition as candidate endophenotypic markers. Neurosci Biobehav Rev 29:399-419
4. Curran HV. 2000. Is MDMA ("Ecstasy'') neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology 42:34-41
5. Curran C, Byrappa N, McBride A. 2004. Stimulant psychosis: systematic review. Br J Psychiatry 185:196-204.
6. Goni-Allo B, Ramos M, Hervias I, Lasheras B, Aguirre N. 2006. Studies on striatal neurotoxicity caused by the 3,4-methylene-dioxymethamphetamine/malnate combination: implications for serotonin/dopamine interactions. J Psychopharmacol 20: 245-256.
7. Gouzoulis-Mayfrank E, Daumann J. 2006. Neurotoxicity of methylenedioxymethamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction 101:348-361.
8. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. 2003. The pharmachology and clinical pharmachology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy''). Pharmacol Rev 55:463-508.
9. Huizinik AC, Ferdinand RF, Van der Ende J, Verhulst FC. 2006. Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study. Br Med J 332:825-828.
10. Kalant H. 2001. The pharmachology and toxicology of "ecstasy'' (MDMA) and related drugs. Can Med Assoc J 165:917-928.
11. Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS. 2000. Striatal serotonin is depleted in brain of a human MDMA (ecstasy) user. Neurology 55:294-296.
12. Lieb K, Zanarini MC, Schmahl C, Linehan MM, Bohus M. 2004. Borderline personality disorder. Lancet 364:453-461.
13. Lieb R, Schuetz CG, Pfister H, von Sydow K, Wittchen HU. 2002. Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 68:195-207.
14. McCann UD, Szabo Z, Scheffe U, Dannals RF, Ricaurte GA. 1998. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy'') on brain serotonin neurons in human beings. Lancet 352:1433-1437.
15. McGuire P, Cope H, Fahy TA. 1994. Diversity of psychopatology associated with use of 3,4-methylenedioxymethamphetamine ("Ecstasy''). Br J Psychiatry 165:391-395.
16. Micallef J, Blin O. 2001. Neurobiology and clinical pharmachology of obsessive-compulsive disorder. Clin Neuropharmacol 24:191-207.
17. Parrott AC, Milani RM, Parmar R, Turner JJD. 2001. Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 159:77-82.
18. Pfohl B, Blum N, Zimmerman M. 1997. Structured interview for DSM-IV personality. Washington, DC: American Psychiatric Press.
19. Poyurovsky M, Weizman A, Weizman R. 2004. Obsessive-compulsive disorder in schizophreina. Clinical characteristic and treatment. CNS Drugs 18:989-1010.
20. Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R. 1998. MDMA ("ecstasy'') consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend 52:85-90.
21. Schifano F. 2000. Potential human neurotoxicity of MDMA ("Ecstasy''): subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies. Neuropsycho-biology 42:25-33.
22. Shih RA, Belmonte PL, Zandi PP. 2004. A review of the evidence from family, twin and adoption studies for a genetic contribution to adult psychiatric disorders. Int Rev Psychiatry 16:260-283.
23. Skodol AE, Gunderson JG, Pfohl B, Widiger TA, Livesley WJ., Siever LJ. 2002. The borderline diagnosis I: Psychopathology, comorbidity, and personality structure. Biol Psychiatry 51:936-950.
24. Topp L, Hando J, Dillon P, Roche A, Solowij N. 1999. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55:105-115.
25. Zohar J, Chropa M, Sasson Y, Amiaz R, Amital D. 2000. Obsessive-compulsive disorder: serotonin and beyond. World J Biol Psychiatry 1:92-100.